Current status of immunotherapy for the treatment of lung cancer

Sanjay Murala, Vamsi Alli, Daniel Kreisel, Andrew E. Gelman, Alexander S. Krupnick

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations


Immunotherapy is a novel approach for the treatment of systemic malignancies. Passive and adaptive immunotherapy have been applied to the treatment of a wide variety of solid tumors such as malignant melanoma (1), renal cell carcinoma (2) and ovarian cancer (3). Several early clinical trials of immune based therapy for both non-small (NSCLC) and small cell lung cancer (SCLC) have demonstrated limited or no success (3,4) but recent trials of antigen-specific cancer immunotherapy have shown early therapeutic potential and are now being rigorously evaluated on a larger scale (5). In this communication we briefly review the historic aspects of immune based therapy for solid cancer, describe therapeutic strategies aimed at targeting lung cancer, and discuss limitations of current therapy and future directions of this field.

Original languageEnglish (US)
Pages (from-to)237-244
Number of pages8
JournalJournal of Thoracic Disease
Issue number4
StatePublished - 2010

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Current status of immunotherapy for the treatment of lung cancer'. Together they form a unique fingerprint.

Cite this